Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Xeljanz
gptkb:Tofacitinib |
| gptkbp:activities |
Janus kinase inhibitor
|
| gptkbp:clinical_trial |
Phase 3
chronic inflammatory conditions |
| gptkbp:contraindication |
active infections
severe liver impairment |
| gptkbp:dosage_form |
5 mg tablet
10 mg tablet 11 mg 11 mg tablet |
| gptkbp:duration |
long-term
|
| gptkbp:education |
avoid live vaccines
report signs of infection adherence to prescribed regimen monitor for liver issues |
| gptkbp:effective_date |
gptkb:2012
FDA approved |
| gptkbp:formulation |
extended-release tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xeljanz XR
|
| gptkbp:ingredients |
tofacitinib
C16 H20 N6 O5 P |
| gptkbp:interacts_with |
immunosuppressants
live vaccines CY P2 C19 inhibitors CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
L04 A A18
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:is_used_for |
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis gptkb:psoriatic_arthritis |
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketed_as |
gptkb:Xeljanz_XR
|
| gptkbp:packaging |
blister pack
|
| gptkbp:population |
adults
|
| gptkbp:provides_information_on |
recommended for moderate to severe cases
|
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:safety_features |
thromboembolic events
malignancy risk gastrointestinal perforations |
| gptkbp:side_effect |
headache
nausea diarrhea increased risk of infections elevated liver enzymes |
| gptkbp:storage |
room temperature
|
| gptkbp:traded_on |
gptkb:Xeljanz
|
| gptkbp:type_of_care |
important for efficacy
|